Please use this identifier to cite or link to this item:
|Title:||Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12.|
|Authors:||Walter, H. S.|
Miall, F. M.
Dyer, M. J.
|Publisher:||Nature Publishing Group|
|Citation:||Blood Cancer Journal (2016) 6, e435;|
|Abstract:||[First paragraph] Obinutuzumab, an afucosylated, type 2 anti-CD20 antibody, showed superior results to rituximab in a head-to-head comparison in combination with chlorambucil in the first-line treatment of chronic lymphocytic leukaemia (CLL) patients with comorbidities in the CLL11 trial (NCT01010061).1 Enhanced activity of obinutuzumab in this setting may reflect better binding to Fc receptors as well as the direct activation of the lysosomal cell death pathway mediated by type 2 CD20 antibodies|
|Rights:||This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/ by/4.0/|
|Appears in Collections:||Published Articles, Dept. of Cancer Studies and Molecular Medicine|
Files in This Item:
|bcj201642a.pdf||Published (publisher PDF)||517.6 kB||Adobe PDF||View/Open|
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.